JP2011513278A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513278A5 JP2011513278A5 JP2010548108A JP2010548108A JP2011513278A5 JP 2011513278 A5 JP2011513278 A5 JP 2011513278A5 JP 2010548108 A JP2010548108 A JP 2010548108A JP 2010548108 A JP2010548108 A JP 2010548108A JP 2011513278 A5 JP2011513278 A5 JP 2011513278A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- treatment
- pain
- alkyl
- amelioration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 4
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 4
- -1 benzitolamide Chemical compound 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229960004126 codeine Drugs 0.000 claims 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 150000002790 naphthalenes Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 1
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims 1
- 239000008896 Opium Substances 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 229960001391 alfentanil Drugs 0.000 claims 1
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 claims 1
- 229960002512 anileridine Drugs 0.000 claims 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 1
- 229950003851 desomorphine Drugs 0.000 claims 1
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 1
- 229960003701 dextromoramide Drugs 0.000 claims 1
- 229960003461 dezocine Drugs 0.000 claims 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 1
- 229960000920 dihydrocodeine Drugs 0.000 claims 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims 1
- 229950010920 eptazocine Drugs 0.000 claims 1
- 229960004578 ethylmorphine Drugs 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- 229950010274 lofentanil Drugs 0.000 claims 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960004300 nicomorphine Drugs 0.000 claims 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 1
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims 1
- 229960004013 normethadone Drugs 0.000 claims 1
- 229950006134 normorphine Drugs 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229960001027 opium Drugs 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960004739 sufentanil Drugs 0.000 claims 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08152104 | 2008-02-28 | ||
| PCT/EP2009/052297 WO2009106574A2 (en) | 2008-02-28 | 2009-02-26 | Combinations for treating hiv-associated pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011513278A JP2011513278A (ja) | 2011-04-28 |
| JP2011513278A5 true JP2011513278A5 (enExample) | 2013-05-02 |
Family
ID=39415383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010548108A Pending JP2011513278A (ja) | 2008-02-28 | 2009-02-26 | カンナビノイド受容体結合化合物およびオピオイドを含む組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090281194A1 (enExample) |
| EP (1) | EP2257281A2 (enExample) |
| JP (1) | JP2011513278A (enExample) |
| KR (1) | KR20100126441A (enExample) |
| CN (1) | CN101945650A (enExample) |
| AU (1) | AU2009218456A1 (enExample) |
| BR (1) | BRPI0907805A2 (enExample) |
| CA (1) | CA2716405A1 (enExample) |
| EA (1) | EA201001363A1 (enExample) |
| MX (1) | MX2010009507A (enExample) |
| WO (1) | WO2009106574A2 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| GB0012795D0 (en) * | 2000-05-25 | 2000-07-19 | Novartis Ag | Organic compounds |
| GB0028702D0 (en) * | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
| US8449908B2 (en) * | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| GB0504950D0 (en) * | 2005-03-10 | 2005-04-20 | Novartis Ag | Organic compositions |
| WO2007006732A1 (en) * | 2005-07-11 | 2007-01-18 | N.V. Organon | Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) |
-
2009
- 2009-02-26 JP JP2010548108A patent/JP2011513278A/ja active Pending
- 2009-02-26 KR KR1020107021410A patent/KR20100126441A/ko not_active Withdrawn
- 2009-02-26 AU AU2009218456A patent/AU2009218456A1/en not_active Abandoned
- 2009-02-26 WO PCT/EP2009/052297 patent/WO2009106574A2/en not_active Ceased
- 2009-02-26 BR BRPI0907805-3A patent/BRPI0907805A2/pt not_active IP Right Cessation
- 2009-02-26 MX MX2010009507A patent/MX2010009507A/es not_active Application Discontinuation
- 2009-02-26 EA EA201001363A patent/EA201001363A1/ru unknown
- 2009-02-26 CN CN2009801054260A patent/CN101945650A/zh active Pending
- 2009-02-26 CA CA2716405A patent/CA2716405A1/en not_active Abandoned
- 2009-02-26 EP EP09715296A patent/EP2257281A2/en not_active Withdrawn
- 2009-03-02 US US12/395,980 patent/US20090281194A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2795158C (en) | Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists | |
| JP2010189403A5 (enExample) | ||
| JP5453151B2 (ja) | 不正使用防止機能付きの経皮的オピオイド送給装置 | |
| JP2011515495A5 (enExample) | ||
| JP2013541567A5 (enExample) | ||
| US20240350479A1 (en) | Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response | |
| JP2006524261A5 (enExample) | ||
| JP2011519930A5 (enExample) | ||
| JP2005530798A5 (enExample) | ||
| JP2017530964A5 (enExample) | ||
| JP2011137020A5 (enExample) | ||
| WO2009120889A2 (en) | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists | |
| TR201908514T4 (tr) | İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ | |
| RU2017112301A (ru) | Стойкие к злоупотреблению фармацевтические композиции | |
| JP2005526124A5 (enExample) | ||
| RU2012124063A (ru) | Лекарственная комбинация с теобромином и ее использование в лечении | |
| JP2013510842A5 (enExample) | ||
| JP2011513278A5 (enExample) | ||
| JP2018534319A5 (enExample) | ||
| CA3005775A1 (en) | Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain | |
| WO2020008370A1 (en) | Transdermal patch |